Proteomics International Laboratories Ltd. announced the appointment of Mr. James Moses to the company's board as an executive director, effective from October 16, 2015. Mr. Moses has extensive experience in investment markets and the media developed in a career spanning 25 years, including a wealth of expertise in advising emerging small-cap public companies. He will work closely with the company's leadership team to develop and implement appropriate strategies to maximise PILL's awareness and penetration in investment markets and with external stakeholders.

Mr. Moses is also the managing director of a leading Australian small-cap focused investor relations and corporate communications practice, and has a successful track record in advising a wide range of companies, including in the life sciences and bio-technology sectors.